Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

McGill researcher develops speedier technique for predicting protein folding pathways

Protein folding has nothing to do with laundry. It is, in fact, one of the central questions in biochemistry. Protein folding is the continual and universal process whereby the long, coiled strings of amino acids that make up proteins in all living things fold into more complex three-dimensional structures.

8 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Aradigm Corporation today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).

6 Jun 2011

Hospitals facing pressure to hold down costs and cut infections; drug shortages reported

For the first time in its history, Medicare will soon track spending on millions of individual beneficiaries, reward hospitals that hold down costs and penalize those whose patients prove most expensive. The administration plans to establish "Medicare spending per beneficiary" as a new measure of hospital performance, just like the mortality rate for heart attack patients and the infection rate for surgery patients.

1 Jun 2011

Bacteria that infect cystic fibrosis patients could help combat MRSA

A bacteria which infects people with cystic fibrosis could help combat other antibiotic-resistant microbes, according to a team from Cardiff and Warwick Universities.

27 May 2011

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

ProteaBio Europe SAS, announced today that the company, in partnership with Mayoly-Spindler, has successfully completed a Phase I/IIA human clinical trial for their MS1819 recombinant Lipase.

26 May 2011

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Researchers devise new genetic technique for IVF embryos

Researchers at the Johns Hopkins University School of Medicine have devised a new technique, which helps couples that are affected by or are carriers of genetic diseases have in vitro fertilized babies free of both the disease in question and other chromosomal abnormalities. The results were reported in the April issue of Fertility and Sterility.

24 May 2011

Scientists discover genetic regions that affect severity of cystic fibrosis

A team of international researchers, including Case Western Reserve University School of Medicine, have discovered regions of the genome that affect the severity of the genetic disease cystic fibrosis, the most common lethal genetic disease affecting children in North America.

24 May 2011

New genetic testing technology for IVG embryos

23 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Researchers discover new genes that influence severity of cystic fibrosis

Johns Hopkins Institute for Genetic Medicine researchers working as part of the North American Cystic Fibrosis Consortium have discovered two regions of the genome that affect the severity of cystic fibrosis, a genetic condition that causes scarring throughout the body, affecting most notably the pancreas and lungs.

23 May 2011

Stem cells from kidneys - World first from Australian scientists

According to Australian scientists, their latest stem cell research breakthrough will bring new treatments for a growing epidemic of chronic kidney disease. They are the first in the world to generate a type of stem cell from human kidney cells. The Melbourne scientists are hoping their discovery will have far-reaching effects in treating the disease.

19 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

Viewpoints: Ryan on 'shared scarcity'; Romney fallout; Baltimore's ambitious health plan

Too many in Washington remain fixated on the next election, at the expense of the next generation. But there is a hidden cost to the shared scarcity mentality — a cost measured in lost prosperity and lost freedom. We face a choice between two futures. We can continue to go down the path toward shared scarcity, or we can choose the path of renewed prosperity.

17 May 2011

Aradigm first quarter total revenue decreases to $0.2 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2011.

12 May 2011

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

NanoBio Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare.

12 May 2011

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

McGill researcher develops speedier technique for predicting protein folding pathways

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Hospitals facing pressure to hold down costs and cut infections; drug shortages reported

Bacteria that infect cystic fibrosis patients could help combat MRSA

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Researchers devise new genetic technique for IVF embryos

Scientists discover genetic regions that affect severity of cystic fibrosis

New genetic testing technology for IVG embryos

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Researchers discover new genes that influence severity of cystic fibrosis

Stem cells from kidneys - World first from Australian scientists

Mpex, Synteract partner for cystic fibrosis fundraising event

Synergy expands GC-C agonist technology to lower cholesterol

Viewpoints: Ryan on 'shared scarcity'; Romney fallout; Baltimore's ambitious health plan

Aradigm first quarter total revenue decreases to $0.2 million

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in